NT-3 mimetics: GTS-301 & GTS-302ГТС-301 / ГТС-302
What is it?
A paired NT-3 research record comparing two loop-4 mimetics with different downstream signaling and animal pharmacology.
Research context
A paired NT-3 research record comparing two loop-4 mimetics with different downstream signaling and animal pharmacology.
What the studies found
animal · 2022
Cell cultures and mice
GTS-301 activated TrkC and TrkB, protected HT-22 cells in injury assays and showed antidepressant-like activity in a mouse forced-swim experiment.
Limit: Preclinical findings do not establish human benefit or safety.
The First Dipeptide Mimetic of Neurotrofin-3: Design and Pharmacological Properties. ↗animal · 2024
Morphine-dependent rats and HT-22 cells
GTS-301 and GTS-302 reduced withdrawal signs in morphine-dependent rats; only GTS-302 reduced withdrawal-associated mechanical allodynia. Cell assays reported different downstream signaling, with AKT/mTOR recruitment for GTS-302. A 2025 erratum is linked separately; quantitative estimates are withheld pending reconciliation.
Limit: Animal withdrawal models are not evidence for treating opioid dependence in people.
Low-Molecular Neurotrophin-3 Mimetics with Different Patterns of Postreceptor Signaling Activation Attenuate Differentially Morphine Withdrawal in Rats. ↗animal · 2025
Mice and rats
GTS-302 altered forced-swim, elevated-plus-maze and object-recognition outcomes in rodents, without changing hot-plate pain sensitivity in the reported tests.
Limit: Preclinical findings do not establish human benefit or safety.
Study of the Pharmacological Activity Spectrum of the New Original NT-3 Mimetic Dipeptide GTS-302. ↗Selected findings, not a systematic review or a treatment recommendation. Combination and related-preparation results cannot be attributed to this compound alone. See each source for access status and remaining limitations.
- Working classification
- Peptide research family
- Research collection
- Neuropeptide research · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —No human treatment trial assessed for this family
- Study methods
- —Member-specific studies; patents and archival leads identified separately
- Independent replication
- —Independent replication not established by the records collected here
- Source access
- —Primary abstracts, selected full texts, patents and explicit retrieval targets
- Safety evidence
- —Cell and animal effects do not establish human safety; analogues may differ
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Inside this research family
Grouping supports navigation. It does not imply equivalent composition, mechanisms, effectiveness or safety.
| Member | Identity | What the source supports |
|---|---|---|
| GTS-301 | Dimeric succinyl-Asn-Asn mimetic | Cell protection and mouse behavioral findings; later rat analgesia experiments are separate outcomes. The First Dipeptide Mimetic of Neurotrofin-3: Design and Pharmacological Properties. ↗ Analgesic Activity of the Low Molecular Weight Neurotrophin-3 Dipeptide Mimetic GTS-301. ↗ |
| GTS-302 | Dimeric hydroxybutyryl-Glu-Asn mimetic | Rodent anxiety-, memory- and antidepressant-like tests; no hot-plate effect reported. Study of the Pharmacological Activity Spectrum of the New Original NT-3 Mimetic Dipeptide GTS-302. ↗ |
| Direct comparison | TrkC/TrkB-related signaling | Different withdrawal and mechanical-pain responses; the 2025 correction must be reconciled. |
Interpretation and open questions
The withdrawal paper reports ERK/PLCγ signaling for GTS-301 and additional AKT/mTOR activation for GTS-302. These are experimental profiles, not treatment-selection rules.
The patent and subsequent papers may describe overlapping experiments. A 2026 stroke-comparison citation remains an acquisition target until the original report is checked.
Linked sources
Explore the research map and unresolved leads ↗
The First Dipeptide Mimetic of Neurotrofin-3: Design and Pharmacological Properties.
Gudasheva TA, Sazonova NM, Tarasiuk AV, Logvinov IO, Antipova TA, Nikiforov DM, Povarnina PY, Seredenin SB · Doklady. Biochemistry and biophysics
GTS-301 activated TrkC and TrkB, protected HT-22 cells in injury assays and showed antidepressant-like activity in a mouse forced-swim experiment.
- Population / setting
- Cell cultures and mice
- What was checked
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Limitations & review scope
- Preclinical findings do not establish human benefit or safety.
- Indexed abstract reviewed; full methods and independent replication require appraisal.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.
Low-Molecular Neurotrophin-3 Mimetics with Different Patterns of Postreceptor Signaling Activation Attenuate Differentially Morphine Withdrawal in Rats.
Kolik LG, Konstantinipolsky MA, Nikolaev SV, Logvinov IO, Antipova TA, Gudasheva TA · Biochemistry. Biokhimiia
GTS-301 and GTS-302 reduced withdrawal signs in morphine-dependent rats; only GTS-302 reduced withdrawal-associated mechanical allodynia. Cell assays reported different downstream signaling, with AKT/mTOR recruitment for GTS-302. A 2025 erratum is linked separately; quantitative estimates are withheld pending reconciliation.
- Population / setting
- Morphine-dependent rats and HT-22 cells
- What was checked
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Limitations & review scope
- Animal withdrawal models are not evidence for treating opioid dependence in people.
- Erratum PMID 40254407 must be reconciled with the full article before relying on numerical estimates.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.
Erratum to: Low-Molecular Neurotrophin-3 Mimetics with Different Patterns of Postreceptor Signaling Activation Attenuate Differentially Morphine Withdrawal in Rats.
Kolik LG, Konstantinipolsky MA, Nikolaev SV, Logvinov IO, Antipova TA, Gudasheva TA · Biochemistry. Biokhimiia
Published correction to the 2024 GTS-301/GTS-302 withdrawal paper. The correction text has not been recovered; this is not another experiment.
- Population / setting
- Correction notice
- What was checked
- Correction metadata and link to original publication checked.
Limitations & review scope
- No abstract available; content of the correction remains to be reviewed.
- Not an independent study or replication.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.
Study of the Pharmacological Activity Spectrum of the New Original NT-3 Mimetic Dipeptide GTS-302.
Nikiforov DM, Povarnina PY, Gudasheva TA, Nadorova AV, Kolik LG, Valdman EA, Vakhitova YV, Seredenin SB · Doklady. Biochemistry and biophysics
GTS-302 altered forced-swim, elevated-plus-maze and object-recognition outcomes in rodents, without changing hot-plate pain sensitivity in the reported tests.
- Population / setting
- Mice and rats
- What was checked
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Limitations & review scope
- Preclinical findings do not establish human benefit or safety.
- Indexed abstract reviewed; full methods and independent replication require appraisal.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.
Analgesic Activity of the Low Molecular Weight Neurotrophin-3 Dipeptide Mimetic GTS-301.
Kolik LG, Konstantinopolsky MA, Sazonova NM, Durnev AD, Gudasheva TA · Doklady. Biochemistry and biophysics
GTS-301 increased rat tail-flick pain thresholds by about 20–30%, with a reported effect lasting at least 24 hours in this experiment. This endpoint is distinct from the GTS-302 hot-plate test.
- Population / setting
- Rats; acute experimental pain testing
- What was checked
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Limitations & review scope
- Preclinical findings do not establish human benefit or safety.
- Indexed abstract reviewed; full methods and independent replication require appraisal.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.
Dimeric dipeptide mimetics of neurotrophin-3 — RU2800369C9
· Primary source linked above
The patent describes the NT-3 mimetic series underlying GTS-301 and GTS-302. Patent examples may overlap with later publications and are not independent clinical evidence.
- Population / setting
- Patent chemistry and preclinical examples
- What was checked
- Selected original-source text checked; full methodological review pending.
Limitations & review scope
- Patent claims are not evidence of approved clinical uses.
- Reconcile shared experiments and corrected publication records.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.